There is no evidence for the existence of complex formation between doxorubicin and glutathione

• Autorzy: Marszalek M , Bartosz M. , Bartosz G.
• Języki publikacji: EN

Abstrakty

EN

Doxorubicin is co-transported with glutathione by several multidrug resistance proteins (MRPs). In order to check whether weak non-covalent aggregates between doxorubicin and glutathione can be formed, which might be substrates for the transporter, the effect of glutathione on the partition coefficient of doxorubicin was studied. No evidence of an effect of glutathione (at levels up to 20 mM) on the partition coefficient of doxorubicin was found in the pH range of 4.0-7.4. These results indicate that non-covalent doxorubicin-glutathione complexes do not form.

Słowa kluczowe

EN

multidrug resistance; chemotherapy; doxorubicin; protein; glutathione; cancer

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2003
• Tom: 08
• Numer: 2
• Opis fizyczny: p.311-315,fig.

Twórcy

autor

Marszalek M

• University of Lodz, Banacha 12-16, 90-237 Lodz, Poland

autor

Bartosz M.

autor

Bartosz G.

Bibliografia

• 1. Marbeuf-Gueye, C., Broxterman, H.J., Dubru, F., Priebe, W. and Garnier-Suillerot, A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol. Pharmacol. 53 (1998) 141-147.
• 2. Sharom, F.J. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 160 (1997) 161-175.
• 3. Keppler, D. Export pumps for glutathione S-conjugates. Free Radic. Biol. Med. 27 (1999) 985-991.
• 4. Rappa, G., Finch, R.A., Sartorelli, A.C. and Lorico, A. New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models. Biochem. Pharmacol. 58 (1999) 557-562.
• 5. Renes, J., de Vries, E.G., Jansen, P.L. and Muller, M. The (patho)physiological functions of the MRP family. Drug Resist. Updat. 3 (2000) 289-302.
• 6. Teodori, E., Dei, S., Scapecchi, S. and Gualtieri, F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 57 (2002) 385-415.
• 7. Vanhoefer, U., Cao, S., Minderman, H., Toth, K., Skenderis, B.S. 2nd, Slovak, M.,L. and Rustum, Y.M. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin. Cancer Res. 2 (1996) 1961- 1968.
• 8. Loe, D.W., Deeley, R.G. and Cole, S.P. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58 (1998) 5130- 5136.
• 9. Rappa, G., Lorico, A., Flavell, R.A. and Sartorelli, A.C. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res. 57 (1997) 5232-5237.
• 10. Lutzky, J., Astor, M.B., Taub, R.N., Baker, M.A., Bhalla, K., Gervasoni, J.E.J., Rosado, M., Stewart, V., Krishna, S. and Hindenburg, A.A. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res. 49 (1989) 4120-4125.
• 11. Broxterman, H.J., Heijn, M. and Lankelma, J. Re: How does the MRP/GS-X pump export doxorubicin? J. Natl. Cancer Inst. 88 (1996) 466-468.
• 12. Versantvoort, C.H., Broxterman, H.J., Bagrij, T., Scheper, R.J. and Twentyman, P.R. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance- associated protein. Br. J. Cancer 72 (1995) 82-89.
• 13. Chambon, M.H. and Viratelle, O.M. Interaction of doxorubicin with ATP: quantification of complexes and effect on its diffusion into DNA-loaded liposomes-implication for ATP-driven transport studies. Anal. Biochem. 263 (1998) 198-207.
• 14. Schindler, M., Grabski, S., Hoff, E. and Simon, S.M. Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry 35 (1996) 2811-2817.